Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL

Estimated average burden

3235-0287

2014

0.5

December 31,

OMB Number:

Expires:

hours per

response

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading Symbol 1. Name and Address of Reporting Person^{*} 5. Relationship of Reporting Person(s) to AGIOS PHARMACEUTICALS INC [AGIO] Issuer **KARSEN PERRY A** (Check all applicable) 3. Date of Earliest Transaction (Month/Day/Year) X Director 10% Owner 05/30/2014 (Last) (First) (Middle) Officer (give Other (specify C/O AGIOS PHARMACEUTICALS, INC., 38 title below) below) SIDNEY STREET, 2ND FLOOR 4. If Amendment, Date of Original Filed 6. Individual or Joint/Group Filing (Check (Month/Day/Year) Applicable Line) (Street) X Form filed by One Reporting Person CAMBRIDGE MA 02139 Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	Transaction Code (Instr. 8)		rities d (A) d of , 4 ai (A) or (D)	or (D) nd 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Instr. 8		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		tion Date	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$ 35.16	05/30/2014		A		12,500		(1)	05/29/2024	Common Stock	12,500	\$ 0	12,500	D	

Explanation of Responses:

1. This option was granted on May 30, 2014. The shares underlying this option vest as to 100% of the underlying shares on May 30, 2015.

<u>/s/ Glenn Goddard, as</u> <u>Attorney-in-Fact for Perry</u> <u>06/05/2014</u> <u>Karsen</u> ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.